Abbvie Inc., of North Chicago, reported net revenues of $8.3 billion in the fourth quarter, a gain of 7.3 percent year-over-year, and 2018 net revenues of $32.75 billion, an increase of 15.2 percent on an operational basis. Abbvie said global sales of Humira (adalimumab) increased 0.5 percent in the fourth quarter based on growth of 9.1 percent in the U.S. and a decline of 14.8 percent operationally outside the U.S., where the therapy faced growing competition from biosimilars.